PET-Scan Tailored De-escalation for p16+ throat cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a treatment plan that may lower (de-escalate) therapy intensity for certain p16+ or HPV-positive throat cancers. It uses PET scan results and tumor features to try to keep cancer control while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed squamous cell throat cancer in the tonsil/base of tongue/throat area (or an unknown primary) that is p16-positive or HPV-positive
- Your PET scan shows high activity (FDG-avid) with SUV max 4.0 or higher
- Your cancer is stage I–II and there are no distant metastases
- You are at least 18 and can safely get the imaging used in the study
- You cannot have certain advanced disease features (cT4, cN3, or cM1), or “matted” lymph nodes/extra spread outside the node
- You must not have had prior treatment for this throat cancer and must be well enough for chemotherapy-type medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether shrinking the “planned radiation area” (elective treatment volumes) can still treat p16-positive oropharyngeal cancer effectively. It may help reduce unnecessary radiation to nearby healthy tissues while keeping the cancer treatment curative.
This Phase 2 study uses HPV test results from your tumor to safely lower (de-intensify) the strength of radiation for some HPV-positive oropharyngeal throat cancers. It aims to reduce side effects while keeping cancer control effective.
This trial tests whether giving less radiation (while using standard chemotherapy) can treat HPV-related throat cancer effectively. It may help reduce radiation exposure while still controlling the cancer.
This trial tests whether we can safely use lower doses of radiation for people with HPV-related throat cancer, while still targeting the areas that need it. The goal is to reduce side effects without lowering the chance of a cure.
This trial tests whether a special PET scan (FMISO PET) can help safely lower the radiation dose for patients with HPV-positive throat cancer. The goal is to reduce side effects while still effectively treating the cancer.
This Phase 2 study tests whether removing the tumor through the mouth, followed by a reduced course of radiation, can control HPV-related (p16+) oropharynx throat cancer. It may help reduce treatment intensity after surgery, while still aiming to keep the cancer from coming back.
Hear when a new Oropharyngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.